A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Inclusion Criteria:

• Female at least 18 years of age, and able to provide informed consent

• Females who are post-menopausal defined, as not have menses for at least 12 monthswithout an alternative medical cause and elevated follicle stimulating hormone inthe postmenopausal range as measured during screening

• Have active FFA that has been diagnosed on or prior to screening visit.

• Have LPPAI score equal to or greater than 5 at screening.

• Have evidence of eyebrow loss at baseline

• Have evidence of hairline recession at baseline

• Have classic presentation with frontal loss of scalp hair

• Negative screening for tuberculosis (Quantiferon Gold, T-spot) within 3 months priorto screening or at the screening visit.

• Agree not to have a live vaccination during the study the exception is herpes zostervaccine

Exclusion Criteria:

• Systemic treatments for FFA within 4 weeks of the baseline visit or 5 half liveswhichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, orimmunosuppressant medications, such as mycophenolate mofetil).

• Dutasteride within the last 6 months

• Have a LPPAI score less than 5 at screening

• Immunocompromised and with risk factors concerning to investigator for studyparticipation

• Previous treatment with an oral JAK inhibitor

• Any condition in the opinion of the investigator which would interfere with thestudy assessments or procedure

• Subject is pregnant or breast feeding

• Surgical intervention including face lifts and micro-blading on the treatment areas

• Any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows)

• Laser or phototherapy intervention on the treatment areas

• Have evidence of active TB or latent TB